EGFR and neoplasm: Using nude mouse xenograft models of erlotinib-resistant human NSCLC NCI-H1975 harboring EGFR L858R/T790M double mutation, mefatinib demonstrated similar or even better anti-tumor activity as compared with afatinib at the same dose.